Clinical Stroke prevention in atrial fibrillation.
Oral anticoagulation therapy has reduced the risk of ischaemic stroke and improved the outcomes for patients with atrial fibrillation considerably. The emergence of the non-vitamin K oral anticoagulants as alternatives to vitamin K antagonists has significantly changed the practice of stroke prevention in atrial fibrillation. As the main complication with antithrombotic therapy is bleeding, physicians should always balance the risk of ischaemic stroke against intracranial haemorrhage and intervene where appropriate to reduce both risks. Individual approach is often mandatory due to heterogeneity of the risks and patient preferences. The purpose of this review is to summarise the current knowledge of the oral anticoagulation therapy in atrial fibrillation patients and guide physicians with the management of anticoagulants based on data from clinical trials and systematic reviews.
['Voukalis|C|C|', 'Shantsila|E|E|', 'Lip|G Y|GY|']
D000284:Administration, Oral D000925:Anticoagulants D001281:Atrial Fibrillation D006801:Humans D020300:Intracranial Hemorrhages D010975:Platelet Aggregation Inhibitors D018570:Risk Assessment D020521:Stroke D014812:Vitamin K
stroke prevention atrial fibrillation oral anticoagulation non-vitamin K oral anticoagulants bleeding risk net clinical benefit risk stratification